These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 8109989)
1. [Circumventing drug resistance in human tumors by antisense ribozyme]. Funato T Gan To Kagaku Ryoho; 1994 Feb; 21(3):336-42. PubMed ID: 8109989 [TBL] [Abstract][Full Text] [Related]
2. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Funato T; Yoshida E; Jiao L; Tone T; Kashani-Sabet M; Scanlon KJ Adv Enzyme Regul; 1992; 32():195-209. PubMed ID: 1496917 [TBL] [Abstract][Full Text] [Related]
3. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Scanlon KJ; Jiao L; Funato T; Wang W; Tone T; Rossi JJ; Kashani-Sabet M Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10591-5. PubMed ID: 1660142 [TBL] [Abstract][Full Text] [Related]
4. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514 [TBL] [Abstract][Full Text] [Related]
5. [Reversal of drug resistance in human cancer cells by anti-oncogenes]. Funato T Gan To Kagaku Ryoho; 1997 Feb; 24(4):395-400. PubMed ID: 9063474 [TBL] [Abstract][Full Text] [Related]
6. [Circumventing multidrug resistance in human cancer by anti-ribozyme]. Funato T Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162 [TBL] [Abstract][Full Text] [Related]
7. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720 [TBL] [Abstract][Full Text] [Related]
8. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Husain A; He G; Venkatraman ES; Spriggs DR Cancer Res; 1998 Mar; 58(6):1120-3. PubMed ID: 9515792 [TBL] [Abstract][Full Text] [Related]
9. Detection of drug resistance in human tumors by in vitro enzymatic amplification. Kashani-Sabet M; Rossi JJ; Lu Y; Ma JX; Chen J; Miyachi H; Scanlon KJ Cancer Res; 1988 Oct; 48(20):5775-8. PubMed ID: 3167836 [TBL] [Abstract][Full Text] [Related]
10. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Scanlon KJ; Kashani-Sabet M; Sowers LC Cancer Commun; 1989; 1(4):269-75. PubMed ID: 2534792 [TBL] [Abstract][Full Text] [Related]
12. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells. Cvijic ME; Chin KV Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205 [TBL] [Abstract][Full Text] [Related]
13. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Bonovich M; Olive M; Reed E; O'Connell B; Vinson C Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245 [TBL] [Abstract][Full Text] [Related]
14. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. Smith ML; Kontny HU; Zhan Q; Sreenath A; O'Connor PM; Fornace AJ Oncogene; 1996 Nov; 13(10):2255-63. PubMed ID: 8950993 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. Kashani-Sabet M; Wang W; Scanlon KJ J Biol Chem; 1990 Jul; 265(19):11285-8. PubMed ID: 2113532 [TBL] [Abstract][Full Text] [Related]
16. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP]. Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609 [TBL] [Abstract][Full Text] [Related]
17. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Materna V; Liedert B; Thomale J; Lage H Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364 [TBL] [Abstract][Full Text] [Related]
18. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. O'Neill CF; Koberle B; Masters JR; Kelland LR Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725 [TBL] [Abstract][Full Text] [Related]
19. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971 [TBL] [Abstract][Full Text] [Related]
20. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]